We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

CNCR ETF Series Solutions Trust Range Cancer Therapeutics

0.12 (0.82%)
Last Updated: 12:30:49
Delayed by 15 minutes


Draw Mode:

Volume 1,045
Bid Price 14.59
Ask Price 14.68
News -
Day High 14.72


52 Week Range


Day Low 14.67
Etf Name Etf Symbol Market Stock Type
ETF Series Solutions Trust Range Cancer Therapeutics CNCR NASDAQ Exchange Traded Fund
  Price Change Price Change % Etf Price Last Trade
0.12 0.82% 14.71 12:30:49
Open Price Low Price High Price Close Price Previous Close
14.67 14.67 14.72 14.59
Trades Etfs Traded VWAP Financial Volume Average Volume 52 Week Range
19 1,045  14.70  15,358 - 9.22 - 18.00
Last Trade Type Quantity Price Currency
12:26:39 100  14.71 USD

ETF Series Solutions Trust Range Cancer Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
11.68M 800.00k - 70k -4.62M -5.77 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

News ETF Series Solutions Tru...

Date Time Source Heading
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No CNCR Message Board. Create One! See More Posts on CNCR Message Board See More Message Board Posts

CNCR Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week15.2915.2914.5715.066,776-0.58-3.79%
1 Month14.0515.9113.9415.2510,3130.664.70%
3 Months17.3318.0013.7716.1336,699-2.62-15.12%
6 Months10.5118.0010.4915.8822,8394.2039.96%
1 Year13.6018.009.2215.3813,1651.118.16%
3 Years30.0832.999.2216.958,941-15.37-51.10%
5 Years20.5135.8189.2220.679,994-5.80-28.28%

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

Your Recent History

Delayed Upgrade Clock